Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Free Report) have been given an average rating of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $6.56.
A number of research firms have recently issued reports on AKYA. JPMorgan Chase & Co. lowered shares of Akoya Biosciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, August 6th. Craig Hallum reduced their price target on shares of Akoya Biosciences from $7.50 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. BTIG Research lowered shares of Akoya Biosciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Morgan Stanley downgraded Akoya Biosciences from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $4.00 to $3.00 in a report on Tuesday, August 6th. Finally, Piper Sandler dropped their price objective on Akoya Biosciences from $6.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th.
Check Out Our Latest Research Report on Akoya Biosciences
Hedge Funds Weigh In On Akoya Biosciences
Akoya Biosciences Price Performance
AKYA stock opened at $2.87 on Wednesday. The company has a current ratio of 2.73, a quick ratio of 1.98 and a debt-to-equity ratio of 3.43. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31. The firm has a market capitalization of $141.74 million, a PE ratio of -1.95 and a beta of 1.36. The firm has a 50-day moving average of $2.70 and a two-hundred day moving average of $2.77.
Akoya Biosciences (NASDAQ:AKYA – Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.27). The business had revenue of $23.16 million during the quarter, compared to analyst estimates of $23.61 million. Akoya Biosciences had a negative net margin of 64.74% and a negative return on equity of 126.38%. During the same period in the prior year, the firm earned ($0.51) earnings per share. On average, analysts forecast that Akoya Biosciences will post -0.98 earnings per share for the current year.
Akoya Biosciences Company Profile
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Further Reading
- Five stocks we like better than Akoya Biosciences
- What is an Earnings Surprise?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Insider Trading – What You Need to Know
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Manufacturing Stocks Investing
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.